Risdiplam is the only orally administered drug accepted for that treatment of SMA. It was FDA permitted in 2020 to be used in patients two months of age and older, and it features being an SMN2 gene splicing modifier resulting in bigger amounts of SMN protein. Oral administration is a https://chancebnyii.blogofchange.com/27165021/new-step-by-step-map-for-le-300